Actively Recruiting
Comparing BUFY01 and SVS20 Eye Drops for Treating Dry Eye Disease A Study on Effectiveness and Safety
Led by TRB Chemedica International SA · Updated on 2026-08-12
80
Participants Needed
2
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
This clinical trial studies dry eye disease by comparing two treatments BUFY01 and SVS20. The research aims to determine if BUFY01 is not worse than SVS20 in improving the signs and symptoms of dry eye disease. The trial is designed as a randomized, quadruple-masked investigation focusing on treatment effects and safety. Participants will receive either BUFY01 or SVS20 eye drops, applied as 1 to 2 drops in each eye as often as needed. These treatments come in single-dose containers and are used daily for three months. The study includes four visits to the trial site where participants are examined, complete questionnaires, and return any unused treatment. During the study, researchers will assess signs of dry eye disease at day 28 and evaluate symptoms as a secondary measure. Participants will be monitored for treatment adherence and safety, with ongoing evaluations during the three-month treatment period. The total participation time includes these visits and treatment use, ending by June 2027.
CONDITIONS
Brief Title
Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
